FULC · CIK 0001680581
What Fulcrum Therapeutics, Inc. told the SEC could break it.
Fulcrum Therapeutics' pipeline is concentrated in a single asset: after a prior candidate missed its primary endpoint, it has only one product candidate in active clinical development — pociredir for sickle cell disease — so a clinical, safety or regulatory setback there would be existential (its ex-U.S. losmapimod program is out-licensed to Sanofi). It is pre-revenue and may stay that way for years, having funded operations largely with $967.5 million in equity and pre-funded-warrant proceeds plus collaboration upfronts against a $594.3 million accumulated deficit, leaving it dependent on continued capital raises. Its path also runs through FDA approval and third-party-payor coverage — exposed to drug-pricing reforms like the IRA's Medicare Part D changes — and it relies on third-party CROs and vendors to run trials and assemble its filings.
4 self-disclosed vulnerabilities, pulled from its own filings — each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Other disclosures
- single-asset pipeline concentration — only one product candidate (pociredir for SCD) in active clinical development after a prior candidate missed its endpointhigh
Fulcrum's clinical pipeline is concentrated in a single asset — after a product candidate failed to meet its primary endpoint, it currently has only one product candidate, pociredir, in active clinical development (for sickle cell disease); a clinical, safety or regulatory setback to pociredir would be existential, with the ex-US losmapimod program now out-licensed to Sanofi.
“As a result, we currently have only one product candidate in active clinical development, pociredir, for the potential treatment of SCD.”
SEC filing →As of 2026
Liquidity & debt
- pre-revenue clinical-stage biopharma — $594.3M accumulated deficit, funded by equity ($967.5M raised) and collaboration upfronts; reliant on ongoing capital raisesmedium
Fulcrum has generated no product revenue and does not expect to for several years (if ever); it had a $594.3 million accumulated deficit and has funded operations primarily with $967.5 million of stock/pre-funded-warrant proceeds plus collaboration upfront payments, and depends on further capital (a $100M ATM, December 2025 underwritten offering) amid capital-markets volatility — a core going-concern/funding risk.
“As of December 31, 2025, we have funded our operations primarily with aggregate gross proceeds of $967.5 million from the sale of shares of our capital stock and pre-funded warrants and from upfront payments received under our collabor”
SEC filing →As of 2026
Regulatory & policy
- FDA approval dependence (NDA/PDUFA review) plus drug-pricing reform (IRA Medicare Part D, Medicaid rebates, 340B) affecting future reimbursementmedium
Fulcrum's future depends on FDA marketing approval (a lengthy NDA review subject to PDUFA goal dates and facility inspection) and, even if approved, on third-party-payor coverage; U.S. drug-pricing legislation — the Inflation Reduction Act's Medicare Part D changes, uncapped Medicaid rebates and 340B expansion — could reduce the prices and reimbursement it can obtain.
“The Inflation Reduction Act of 2022, or IRA, includes several provisions that may impact our business to varying degrees, including provisions that reduce the out-of-pocket cap for Medicare Part D beneficiaries to $2,000 starting in 2025; impose new manufacturer financial liability on certain drugs unde”
Supplier concentration
- reliance on third-party CROs, consultants and vendors for clinical trials, manufacturing information and marketing-approval filingsmedium
Fulcrum has only limited experience filing marketing applications and expects to rely on third-party clinical research organizations and other consultants/vendors to conduct trials and assemble the extensive preclinical, clinical and manufacturing data needed for regulatory submissions; failures or delays by these third parties could jeopardize approvals and timelines.
“expect to rely on third-party clinical research organizations or other third-party consultants or vendors to assist us in this process.”
SEC filing →As of 2026
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings — including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its customers
“we entered into a collaboration and license agreement with Sanofi, pursuant to which we granted Sanofi an exclusive license under certain intellectual property rights to commercialize losmapimod, an oral small molecule that we were developing for the treatment of FSHD outside of the United States and received an upfront payment of $80.0 million.”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch